US equities
|
NVDA
$241.50
▲+1.09%
SPCX
$173.78
▲+1.57%
MU
$1,063.52
▼-0.04%
AMD
$654.76
▲+3.64%
MRVL
$288.17
▲+6.24%
SNDK
$1,673.33
▼-1.81%
AVGO
$378.20
▲+4.33%
TSLA
$380.74
▲+0.53%
NVDA
$241.50
▲+1.09%
SPCX
$173.78
▲+1.57%
MU
$1,063.52
▼-0.04%
AMD
$654.76
▲+3.64%
MRVL
$288.17
▲+6.24%
SNDK
$1,673.33
▼-1.81%
AVGO
$378.20
▲+4.33%
TSLA
$380.74
▲+0.53%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Black Diamond Therapeutics, Inc. - Common Stock
(NQ:
BDTX
)
1.920
-0.020 (-1.03%)
Delayed Quote
Updated: 11:35 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Black Diamond Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 19, 2025
Via
Benzinga
Wednesday's session: gap up and gap down stocks
↗
March 19, 2025
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million
↗
March 19, 2025
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone...
Via
Benzinga
Discover the top movers in Wednesday's pre-market session.
↗
March 19, 2025
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via
Chartmill
Looking Into Black Diamond Therapeutic's Recent Short Interest
↗
August 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
March 19, 2025
Via
Benzinga
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
March 19, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 06, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
↗
January 13, 2025
Via
Benzinga
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 05, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 01, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
October 07, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements
September 23, 2024
Via
AB Newswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
↗
September 23, 2024
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows...
Via
Benzinga
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
September 23, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
September 22, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
September 14, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
August 08, 2024
From
Gyre Therapeutics, Inc.
Via
GlobeNewswire
BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024
↗
August 06, 2024
BDTX stock results show that Black Diamond Therapeutic beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
June 11, 2024
Via
Benzinga
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 29, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024
↗
May 09, 2024
BDTX stock results show that Black Diamond Therapeutic beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
April 23, 2024
Via
Benzinga
Black Diamond Therapeutics Announces Changes to Board of Directors
April 11, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
April 07, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
April 03, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
